Literature DB >> 23403316

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.

Asfar S Azmi1, Ayad Al-Katib, Amro Aboukameel, Dilara McCauley, Michael Kauffman, Sharon Shacham, Ramzi M Mohammad.   

Abstract

The nuclear export protein chromosome maintenance region 1, found to be elevated in non-Hodgkin's lymphomas, controls localization of critical tumor suppressor proteins. Nuclear localization of tumor suppressor proteins is necessary for their cell surveillance function. However, their nuclear exclusion by chromosome maintenance region 1 renders them ineffective making this nuclear transporter an attractive therapeutic target. We have identified selective inhibitors of nuclear export that lock tumor suppressor proteins in the cell nucleus leading to apoptosis of lymphoid but not normal cells. Our inhibitors induce tumor suppressor protein nuclear retention-dependent growth inhibition and apoptosis in a panel of non-Hodgkin's lymphoma cell lines. Western blot of nuclear protein fraction and confocal microscopy analysis demonstrated retention of major tumor suppressor proteins in the cell nucleus. Co-immunoprecipitation studies showed disruption of the tumor suppressor protein-chromosome maintenance region 1 interaction. Small inhibitor RNA knockdown of two major tumor suppressor proteins, p53 in wild-type protein-53 and protein 73 in mutant-protein-53, abrogated inhibitor activity. Oral administration of related inhibitor at 75 and 150 mg/kg resulted in 65 and 70% tumor reduction, respectively and subcutaneous injections of inhibitor (25 and 75 mg/kg) resulted in 70 and 74% suppression of non-Hodgkin's lymphoma tumor growth with no toxicity; residual tumors showed activation of the protein 73 pathway. Our study verifies chromosome maintenance region 1 as a therapeutic target in non-Hodgkin's lymphoma, indicating that this nuclear export protein warrants further clinical investigations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403316      PMCID: PMC3696614          DOI: 10.3324/haematol.2012.074781

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  34 in total

Review 1.  Regulation of nuclear localization during signaling.

Authors:  M S Cyert
Journal:  J Biol Chem       Date:  2001-04-12       Impact factor: 5.157

Review 2.  Nuclear transport and cancer: from mechanism to intervention.

Authors:  Tweeny R Kau; Jeffrey C Way; Pamela A Silver
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

3.  A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells.

Authors:  Tweeny R Kau; Frank Schroeder; Shivapriya Ramaswamy; Cheryl L Wojciechowski; Jean J Zhao; Thomas M Roberts; Jon Clardy; William R Sellers; Pamela A Silver
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

Review 4.  Karyopherins: from nuclear-transport mediators to nuclear-function regulators.

Authors:  Nima Mosammaparast; Lucy F Pemberton
Journal:  Trends Cell Biol       Date:  2004-10       Impact factor: 20.808

5.  The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.

Authors:  R M Mohammad; N R Wall; J A Dutcher; A M Al-Katib
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

6.  Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation.

Authors:  X Wang; A Zalcenstein; M Oren
Journal:  Cell Death Differ       Date:  2003-04       Impact factor: 15.828

7.  Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model.

Authors:  A al-Katib; R Mohammad; M Hamdan; A N Mohamed; M Dan; M R Smith
Journal:  Blood       Date:  1993-06-01       Impact factor: 22.113

Review 8.  The epidemiology of non-Hodgkin's lymphoma.

Authors:  Susan G Fisher; Richard I Fisher
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

9.  Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice.

Authors:  Asfar S Azmi; Amro Aboukameel; Bin Bao; Fazlul H Sarkar; Philip A Philip; Michael Kauffman; Sharon Shacham; Ramzi M Mohammad
Journal:  Gastroenterology       Date:  2012-10-23       Impact factor: 22.682

10.  Phase I trial of elactocin.

Authors:  E S Newlands; G J Rustin; M H Brampton
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more
  33 in total

Review 1.  Nuclear export mediated regulation of microRNAs: potential target for drug intervention.

Authors:  Irfana Muqbil; Bin Bao; Abdul Badi Abou-Samra; Ramzi M Mohammad; Asfar S Azmi
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

Review 2.  Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Authors:  Joel G Turner; Jana Dawson; Christopher L Cubitt; Rachid Baz; Daniel M Sullivan
Journal:  Semin Cancer Biol       Date:  2014-03-12       Impact factor: 15.707

Review 3.  Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?

Authors:  Irfana Muqbil; Jack Wu; Amro Aboukameel; Ramzi M Mohammad; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2014-06-17       Impact factor: 15.707

4.  Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.

Authors:  Edward F Attiyeh; John M Maris; Richard Lock; C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Gorlick; E Anders Kolb; Stephen T Keir; Jianrong Wu; Yosef Landesman; Sharon Shacham; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2015-09-23       Impact factor: 3.167

5.  Providing activation-induced cytidine deaminase (AID) to nuclear export inhibitors. Response to: "Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase".

Authors:  Asfar S Azmi; Ramzi M Mohammad
Journal:  Haematologica       Date:  2013-09       Impact factor: 9.941

6.  Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase (AID).

Authors:  Velizar Shivarov; Petya Dimitrova; Tchavdar Vassilev
Journal:  Haematologica       Date:  2013-09       Impact factor: 9.941

Review 7.  Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.

Authors:  Shogo Ohkoshi; Masahiko Yano; Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.

Authors:  Yun Zheng; Sigal Gery; Haibo Sun; Sharon Shacham; Michael Kauffman; H Phillip Koeffler
Journal:  Cancer Chemother Pharmacol       Date:  2014-07-17       Impact factor: 3.333

Review 9.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

Review 10.  Nuclear trafficking in health and disease.

Authors:  Amir Mor; Michael A White; Beatriz M A Fontoura
Journal:  Curr Opin Cell Biol       Date:  2014-02-11       Impact factor: 8.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.